

# Steve Vucic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378692/publications.pdf>

Version: 2024-02-01

74  
papers

6,225  
citations

117453

34  
h-index

88477

70  
g-index

74  
all docs

74  
docs citations

74  
times ranked

5852  
citing authors

#	ARTICLE	IF	CITATIONS
1	Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2022, 65, 43-50.	1.0	6
2	Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 105-106.	0.5	3
3	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 321-328.	1.1	4
4	The split-elbow index: A biomarker of the split elbow sign in ALS. <i>Clinical Neurophysiology Practice</i> , 2022, 7, 16-20.	0.6	4
5	Long read sequencing overcomes challenges in the diagnosis of <i>SORD</i> neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 120-126.	1.4	6
6	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 668-678.	0.9	35
7	Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN). <i>Clinical Neurophysiology</i> , 2022, 140, 228-238.	0.7	2
8	Pathophysiological associations of transcallosal dysfunction in ALS. <i>European Journal of Neurology</i> , 2021, 28, 1172-1180.	1.7	12
9	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 86-95.	0.9	174
10	Improving clinical trial outcomes in amyotrophic lateral sclerosis. <i>Nature Reviews Neurology</i> , 2021, 17, 104-118.	4.9	152
11	Neurotoxicity and ALS: Insights into Pathogenesis. , 2021, , 1-19.		0
12	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. <i>BMJ Open</i> , 2021, 11, e041479.	0.8	33
13	Diagnostic Utility of Gold Coast Criteria in <i>Amyotrophic Lateral Sclerosis</i> . <i>Annals of Neurology</i> , 2021, 89, 979-986.	2.8	68
14	Advances in the understanding of sensory neuronopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 343-343.	0.9	0
15	P300 jitter latency, brain-computer interface and amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2021, 132, 614-615.	0.7	1
16	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 96, e2090-e2097.	1.5	12
17	Utility of Transcranial Magnetic Stimulation in Studying Upper Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. <i>Brain Sciences</i> , 2021, 11, 906.	1.1	4
18	The Upper Motor Neuronâ€™ Improved Knowledge from ALS and Related Clinical Disorders. <i>Brain Sciences</i> , 2021, 11, 958.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1126-1130.	0.9	25
20	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. <i>Muscle and Nerve</i> , 2021, 64, 532-537.	1.0	16
21	Review Article "Spotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Date". <i>International Journal of General Medicine</i> , 2021, Volume 14, 4579-4604.	0.8	7
22	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1991-1999.	1.7	18
23	Nerve biopsy in acquired neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2021, 26 Suppl 2, S21-S41.	1.4	2
24	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. <i>Muscle and Nerve</i> , 2021, 63, 371-383.	1.0	13
25	Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , 2020, 131, 308-323.	0.7	63
26	Split-hand sign: clinical feature of spinal bulbar muscular atrophy?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1143-1144.	0.9	0
27	ALS is a multistep process in South Korean, Japanese, and Australian patients. <i>Neurology</i> , 2020, 94, e1657-e1663.	1.5	39
28	Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study). <i>Medicine (United States)</i> , 2020, 99, e18904.	0.4	23
29	Reproducibility of motor unit number index and MScanFit motor unit number estimation across intrinsic hand muscles. <i>Muscle and Nerve</i> , 2020, 62, 192-200.	1.0	17
30	Cortical hyperexcitability evolves with disease progression in ALS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 733-741.	1.7	45
31	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1373-1382.	1.7	19
32	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 532-537.	1.1	22
33	Split elbow sign: more evidence for the importance of cortical dysfunction in ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 729-729.	0.9	10
34	Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 681.	4.5	120
35	Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. <i>Neuroscience Letters</i> , 2018, 674, 18-23.	1.0	34
36	Physiological changes in neurodegeneration "mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	4.9	72

#	ARTICLE	IF	CITATIONS
37	Neurofascinâ€155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. <i>Muscle and Nerve</i> , 2018, 57, 848-851.	1.0	37
38	Utility of threshold tracking transcranial magnetic stimulation in ALS. <i>Clinical Neurophysiology Practice</i> , 2018, 3, 164-172.	0.6	51
39	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. <i>Neurology</i> , 2018, 91, e1669-e1676.	1.5	67
40	Physiological Processes Underlying Short Interval Intracortical Facilitation in the Human Motor Cortex. <i>Frontiers in Neuroscience</i> , 2018, 12, 240.	1.4	31
41	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. <i>Clinical Neurophysiology</i> , 2018, 129, 2162-2169.	0.7	15
42	Functional Biomarkers for Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 1141.	1.1	23
43	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2017, 128, 1075-1082.	0.7	34
44	Motor neurone disease: progress and challenges. <i>Medical Journal of Australia</i> , 2017, 206, 357-362.	0.8	28
45	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. <i>BMJ Open</i> , 2016, 6, e012054.	0.8	48
46	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. <i>Clinical Neurophysiology</i> , 2016, 127, 2684-2691.	0.7	74
47	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. <i>Nature Reviews Neurology</i> , 2016, 12, 651-661.	4.9	165
48	Diagnostic criteria in amyotrophic lateral sclerosis. <i>Neurology</i> , 2016, 87, 684-690.	1.5	46
49	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.5	76
50	Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1147-1154.	1.4	22
51	Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 580-588.	1.1	58
52	Rate of disease progression: a prognostic biomarker in ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 628-632.	0.9	123
53	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. <i>Lancet Neurology</i> , The, 2015, 14, 478-484.	4.9	164
54	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2015, 262, 1424-1432.	1.8	47

#	ARTICLE	IF	CITATIONS
55	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. <i>Clinical Neurophysiology</i> , 2015, 126, 803-809.	0.7	140
56	Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2014, 9, e87124.	1.1	75
57	Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 250-256.	1.1	27
58	Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls. <i>Muscle and Nerve</i> , 2014, 49, 836-844.	1.0	22
59	ALS pathophysiology: Insights from the split-hand phenomenon. <i>Clinical Neurophysiology</i> , 2014, 125, 186-193.	0.7	44
60	Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 315-318.	1.1	46
61	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2013, 124, 410-416.	0.7	97
62	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. <i>Brain</i> , 2013, 136, 1361-1370.	3.7	123
63	FOSMN syndrome. <i>Neurology</i> , 2012, 79, 73-79.	1.5	47
64	Cortical excitability distinguishes ALS from mimic disorders. <i>Clinical Neurophysiology</i> , 2011, 122, 1860-1866.	0.7	122
65	Amyotrophic lateral sclerosis. <i>Lancet, The</i> , 2011, 377, 942-955.	6.3	2,182
66	Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 33-38.	2.3	47
67	Upregulation of persistent sodium conductances in familial ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 222-227.	0.9	86
68	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. <i>Brain</i> , 2010, 133, 2727-2733.	3.7	29
69	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. <i>Brain</i> , 2008, 131, 1540-1550.	3.7	391
70	Pathophysiologic insights into motor axonal function in Kennedy disease. <i>Neurology</i> , 2007, 69, 1828-1835.	1.5	27
71	Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 849-852.	0.9	97
72	Assessment of cortical excitability using threshold tracking techniques. <i>Muscle and Nerve</i> , 2006, 33, 477-486.	1.0	162

#	ARTICLE	IF	CITATIONS
73	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. <i>Brain</i> , 2006, 129, 2436-2446.	3.7	284
74	Autosomal recessive hereditary spastic paraparesis with thin corpus callosum; report of two sisters. <i>Journal of Clinical Neuroscience</i> , 2004, 11, 427-430.	0.8	4